GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-14
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $0.00.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was -$34.00K.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $0.00.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $3.00M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | -$34.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | -$34.00K derived: sum of 3 quarters · filed 2026-05-15 | -$1.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | -$34.00K derived: sum of 2 quarters · filed 2026-03-06 | -$1.00K derived: sum of 3 quarters · filed 2026-03-06 | $0.00 10-K · filed 2026-03-02 | |
| 2025-09-30 | -$34.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | -$1.00K derived: sum of 2 quarters · filed 2026-03-06 | $0.00 10-Q/A · filed 2026-03-06 | ||
| 2025-06-30 | $33.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2026-03-06 | $34.00K 10-Q/A · filed 2026-03-06 | |||
| 2025-03-31 | $1.00K 10-Q · filed 2025-05-15 | ||||
| 2022-12-31 | $3.00M 10-K · filed 2024-03-26 | $3.03M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |